Anesthetic Effect - Pipeline Review, H1 2016
Summary
Global Markets Directs, Anesthetic Effect - Pipeline Review, H1 2016, provides an overview of the Anesthetic Effect pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Anesthetic Effect, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Anesthetic Effect and features dormant and discontinued projects.
Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Anesthetic Effect
- The report reviews pipeline therapeutics for Anesthetic Effect by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Anesthetic Effect therapeutics and enlists all their major and minor projects
- The report assesses Anesthetic Effect therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Anesthetic Effect
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Anesthetic Effect
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Anesthetic Effect pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table Of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Anesthetic Effect Overview 9
Therapeutics Development 10
Pipeline Products for Anesthetic Effect - Overview 10
Pipeline Products for Anesthetic Effect - Comparative Analysis 11
Anesthetic Effect - Therapeutics under Development by Companies 12
Anesthetic Effect - Therapeutics under Investigation by Universities/Institutes 14
Anesthetic Effect - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Unknown Stage Products 18
Anesthetic Effect - Products under Development by Companies 19
Anesthetic Effect - Products under Investigation by Universities/Institutes 20
Anesthetic Effect - Companies Involved in Therapeutics Development 21
Drawbridge Pharmaceuticals Pty Ltd 21
Jiangsu Hengrui Medicine Co., Ltd. 22
Juniper Pharmaceuticals, Inc. 23
Lipicard Technologies Limited 24
NanoMedex Pharmaceuticals, Inc. 25
Orbis Biosciences, Inc. 26
Paion AG 27
Phosphagenics Limited 28
Physica Pharma SAS 29
Primex Pharmaceuticals Oy 30
Proteus SA 31
Sphaera Pharma Pvt. Ltd. 32
Taiwan Liposome Company, Ltd. 33
The Medicines Company 34
Anesthetic Effect - Therapeutics Assessment 35
Assessment by Monotherapy Products 35
Assessment by Combination Products 36
Assessment by Target 37
Assessment by Mechanism of Action 39
Assessment by Route of Administration 41
Assessment by Molecule Type 43
Drug Profiles 44
(oxymetazoline hydrochloride + tetracaine hydrochloride) - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
ABP-700 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
ADV-6209 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
alphaxalone - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
bupivacaine hydrochloride - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
bupivacaine hydrochloride ER - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
carboetomidate - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
gabafol - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
HSK-3486 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
lidocaine hydrochloride ER - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
LT-1121 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
LT-1123 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
methoxycarbonyl carboetomidate - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
methoxycarbonyl etomidate - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
neosaxitoxin - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
PB-5109 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
PHY-301 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
propofol - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
propofol microemulsion - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
propofol-DM - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
remimazolam - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
remimazolam - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
Small Molecules to Inhibit NMDA Receptor for Anesthesia - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
Anesthetic Effect - Recent Pipeline Updates 76
Anesthetic Effect - Dormant Projects 82
Anesthetic Effect - Discontinued Products 84
Anesthetic Effect - Product Development Milestones 85
Featured News & Press Releases 85
Dec 01, 2015: PAION Announces Initiation of U.S. Clinical Safety Trial of Remimazolam in High Risk Patients Undergoing Colonoscopy 85
Oct 26, 2015: Results of First-in-Man Study with Investigational Anesthetic ABP-700 Presented at ANESTHESIOLOGY 2015 and International Society of Anesthetic Pharmacology Annual Meetings 85
Oct 22, 2015: The Medicines Company To Present Data on Potentially Innovative Surgical Anesthetic at American Society of Anesthesiologists 2015 Meeting 86
Oct 12, 2015: Remimazolam Posters at Anesthesiology 2015 87
Aug 11, 2015: Paion Starts EU Phase III Study With Remimazolam In The Indication General Anesthesia 88
Jun 15, 2015: Juniper Pharmaceuticals Announces First Patient Enrolled in Phase II Study of COL-1077 as an Acute-Use Anesthetic for Minimally-Invasive Gynecologic Procedures 89
Jun 08, 2015: PAION Announces Initiation Of Second U.S. Phase 3 Clinical Trial Of Remimazolam For Procedural Sedation During Bronchoscopy 90
Feb 10, 2015: Drawbridge Pharmaceuticals granted Notice of Allowance for divisional patent in the United States 90
Nov 05, 2014: Paion's Partner Ono Decides Not To File For Regulatory Approval Of REMIMAZOLAM In Japan And Will Return Its REMIMAZOLAM Rights For Japan To Paion 91
Oct 14, 2014: Invitation To Conference Call Of Paion About The Project Status Of Remimazolam In Japan 92
Appendix 93
Methodology 93
Coverage 93
Secondary Research 93
Primary Research 93
Expert Panel Validation 93
Contact Us 93
Disclaimer 94
List Of Tables
Number of Products under Development for Anesthetic Effect, H1 2016 10
Number of Products under Development for Anesthetic Effect - Comparative Analysis, H1 2016 11
Number of Products under Development by Companies, H1 2016 13
Number of Products under Investigation by Universities/Institutes, H1 2016 14
Comparative Analysis by Late Stage Development, H1 2016 15
Comparative Analysis by Clinical Stage Development, H1 2016 16
Comparative Analysis by Early Stage Development, H1 2016 17
Comparative Analysis by Unknown Stage Development, H1 2016 18
Products under Development by Companies, H1 2016 19
Products under Investigation by Universities/Institutes, H1 2016 20
Anesthetic Effect - Pipeline by Drawbridge Pharmaceuticals Pty Ltd, H1 2016 21
Anesthetic Effect - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H1 2016 22
Anesthetic Effect - Pipeline by Juniper Pharmaceuticals, Inc., H1 2016 23
Anesthetic Effect - Pipeline by Lipicard Technologies Limited, H1 2016 24
Anesthetic Effect - Pipeline by NanoMedex Pharmaceuticals, Inc., H1 2016 25
Anesthetic Effect - Pipeline by Orbis Biosciences, Inc., H1 2016 26
Anesthetic Effect - Pipeline by Paion AG, H1 2016 27
Anesthetic Effect - Pipeline by Phosphagenics Limited, H1 2016 28
Anesthetic Effect - Pipeline by Physica Pharma SAS, H1 2016 29
Anesthetic Effect - Pipeline by Primex Pharmaceuticals Oy, H1 2016 30
Anesthetic Effect - Pipeline by Proteus SA, H1 2016 31
Anesthetic Effect - Pipeline by Sphaera Pharma Pvt. Ltd., H1 2016 32
Anesthetic Effect - Pipeline by Taiwan Liposome Company, Ltd., H1 2016 33
Anesthetic Effect - Pipeline by The Medicines Company, H1 2016 34
Assessment by Monotherapy Products, H1 2016 35
Assessment by Combination Products, H1 2016 36
Number of Products by Stage and Target, H1 2016 38
Number of Products by Stage and Mechanism of Action, H1 2016 40
Number of Products by Stage and Route of Administration, H1 2016 42
Number of Products by Stage and Molecule Type, H1 2016 43
Anesthetic Effect Therapeutics - Recent Pipeline Updates, H1 2016 76
Anesthetic Effect - Dormant Projects, H1 2016 82
Anesthetic Effect - Dormant Projects (Contd..1), H1 2016 83
Anesthetic Effect - Discontinued Products, H1 2016 84
List Of Figures
Number of Products under Development for Anesthetic Effect, H1 2016 10
Number of Products under Development for Anesthetic Effect - Comparative Analysis, H1 2016 11
Number of Products under Development by Companies, H1 2016 12
Comparative Analysis by Late Stage Development, H1 2016 15
Comparative Analysis by Clinical Stage Development, H1 2016 16
Comparative Analysis by Early Stage Products, H1 2016 17
Assessment by Monotherapy Products, H1 2016 35
Number of Products by Targets, H1 2016 37
Number of Products by Stage and Targets, H1 2016 37
Number of Products by Mechanism of Actions, H1 2016 39
Number of Products by Stage and Mechanism of Actions, H1 2016 39
Number of Products by Routes of Administration, H1 2016 41
Number of Products by Stage and Routes of Administration, H1 2016 41
Number of Products by Stage and Molecule Types, H1 2016 43
